KAYA17 Products

KAYA17 has a complete Point of Need testing solution - the nCoVega saliva test for COVID-19 with the following features:


98% Sensitivity
98% Specificity


Sample to Results
in 15 Minutes


Only Saliva Test in
Ultra-Portable Kit


Needs Minimal


Quick testing
for busy places

Click for Product Brochure of nCoVega Saliva COVID test

One KAYA17 reader can run 30 tests per hour at a testing site and can be scaled up to 300 tests per hour with ten readers, thus making it an ideal candidate for rapid testing at airports, resorts, events, cruise lines, stations, schools, workplaces, and hospitals.

Future KAYA17 Products

The KAYA 17 Point of Care platform technology is a New Antigen Test with a breakthrough level of sensitivity combined with speed and ease of use, opening a wide range of applications. WIth laboratory level accuracy, primary care physicians, specialists, pharmacists and other caregivers can reliably deliver laboratory-accurate diagnoses on-site, within minutes. With a minor change to the reagents, rapid Point-of-Care tests can be developed for other medical diagnostic targets. No change will be required for the cartridge and reader. This allows the technology to be used in the rapid diagnosis of several other diseases and conditions as well, with the same level of accuracy and efficiency.

Cervical Cancer: Test validated with patient sample at All India Institute of Medical Science (AIIMS).
Food Diagnosis: Test validated for E. Coli, Salmonella, Listeria
Allergy Testing: Under development.

Other Tests: The KAYA17 technology base goes beyond COVID-19 testing, using the same platform. The following tests are candidates for future development:

US and other Markets: Hepatitis B, UTI, Cardiac Markers, Influenza A & B, Nora Virus, Strep Throat, Staph Infection, Sepsis
Developing Countries: Cervical Cancers, UTI, Hepatitis B & C, HIV, Food bacteria (E. Coli, Salmonella, Listeria), Water Testing, Dengue, Chikungunya

KAYA17 on CNBC Advancements Program